Simon Melov, PhD, Professor
Identifying molecular hallmarks of aging to guide the development of anti-aging therapies
Simon Melov is one of the founding faculty of the Institute, and has been at the Buck since its doors opened in 1999. He has broad expertise in multiple domains and model systems of aging, including C. elegans biology, functional decline with age in mice, the role of endogenous oxidative stress in the mitochondria, exercise physiology and age-related disease.
Over the last few years, a key focus of the Melov lab has been to define what “aging" means in the context of different organ systems in aging mice, and to use non-invasive techniques to quantitate and enumerate such functional changes. The end goal is to be able to relate age-related functional decline in mice to human aging. Other research interests include the development of molecular techniques to better understand how single cells change with age, and then to use that understanding to elucidate how such changes impact tissue function.
Dr. Melov has always placed a high value on collaborative studies, believing that in the current research environment, the best science is done by synergizing expertise. Based on multiple collaborations, he has published with most of the faculty at the Institute, and has maintained collaborations with researchers at other locations as well. This approach has consistently resulted in multiple discoveries being made in conjunction with other laboratories within the institute, as well as those outside.
Dr. Melov received his PhD in Biochemistry from the University of London in the UK. He held positions at Emory University in Atlanta and at the University of Colorado in Boulder before joining the faculty of the Buck Institute as an associate professor in 1999.
Dr. Melov welcomes media inquiries on the following subjects:
Genetics of aging, aging and exercise, antioxidants and aging.
“Efforts to extend healthspan by delaying the aging process are moving from ‘impossible’ to ‘inevitable.’ The Buck Institute is uniquely positioned to play a pivotal role in this new area of medicine.”
Simon Melov, PhD